Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

NCT03452943 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Tourette Syndrome

Interventions

DRUG: TEV-50717
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Collaborators

[object Object]